IBC101 / Liminatus - LARVOL DELTA

Innovation Bio Approved Clinical Approval of Dual-Target CAR-T ’Indura-Cell’ [Google translation] (News1 Korea) - "Innovation Bio is entering clinical trials of its dual-target CAR-T therapy 'Indura-Cell'...According to the industry on the 12th, Innovation Bio received approval from the Ministry of Food and Drug Safety the day before for the Phase 1/2a clinical trial plan of Indura-Cell....This clinical trial will be conducted in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL). This study is to evaluate the safety, tolerability, and efficacy of Indura-Cell. It will be carried out in a dose-escalation method for a single group at a single institution at the Catholic University of Seoul St. Mary's Hospital."

New P1/2 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology